Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A four-drug multimodal formulation combining a long-acting local anesthetic (bupivacaine) with three adjuvants (clonidine, buprenorphine, and dexamethasone) designed for prolonged single-injection peripheral nerve blocks in regional anesthesia. This combination has been studied for its efficacy in extending the duration of analgesia and reducing postoperative pain and opioid use compared to bupivacaine alone. Laboratory studies have confirmed both chemical compatibility in solution and in vivo safety, producing reversible sensory and motor nerve blocks without causing long-term nerve damage. Research continues to explore its potential as an alternative to continuous catheter-based techniques.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + clonidine + buprenorphine + dexamethasone.